Praxis Precision [PRAX] vs Vaxcyte [PCVX] Detailed Stock Comparison
TLDR: Quick Comparison Summary
Based on 16 vital metrics comparison: Praxis Precision Medicines Inc. wins in 4 metrics, Vaxcyte Inc. wins in 8 metrics, with 2 ties. Vaxcyte Inc. appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Praxis Precision Medicines Inc. | Vaxcyte Inc. | Better |
|---|---|---|---|
| P/E Ratio (TTM) | N/A | -10.79 | N/A |
| Price-to-Book Ratio | 9.46 | 2.97 | Vaxcyte Inc. |
| Debt-to-Equity Ratio | 0.01 | 4.38 | Praxis Precision Medicines Inc. |
| PEG Ratio | -38.31 | -8.34 | Vaxcyte Inc. |
| EV/EBITDA | -26.32 | -8.05 | Vaxcyte Inc. |
| Profit Margin (TTM) | 0.00% | 0.00% | Tie |
| Operating Margin (TTM) | 0.00% | 0.00% | Tie |
| Return on Equity | -45.83% | -25.59% | Vaxcyte Inc. |
| Return on Assets (TTM) | -28.69% | -17.73% | Vaxcyte Inc. |
| Free Cash Flow (TTM) | $-249.12M | $-712.55M | Praxis Precision Medicines Inc. |
| 1-Year Return | 501.76% | 37.33% | Praxis Precision Medicines Inc. |
| Enterprise Value | $8.58B | $7.30B | Praxis Precision Medicines Inc. |
| Revenue per Share (TTM) | N/A | $0 | N/A |
| Earnings per Share (Diluted) | $-13.48 | $-5.63 | Vaxcyte Inc. |
| Beta (Stock Volatility) | 2.97 | 1.39 | Vaxcyte Inc. |
| Short % of Float | 14.21% | 10.52% | Vaxcyte Inc. |
Praxis Precision Medicines Inc. vs Vaxcyte Inc. Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Praxis Precision Medicines Inc. | -0.77% | 4.46% | -22.78% | -13.27% | -4.29% | -7.63% |
| Vaxcyte Inc. | 4.42% | 6.97% | -5.40% | -10.90% | 11.77% | 6.67% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Praxis Precision Medicines Inc. | 501.76% | 1,560.93% | -17.42% | -36.07% | -36.07% | -36.07% |
| Vaxcyte Inc. | 37.33% | -7.21% | 120.95% | 81.49% | 81.49% | 81.49% |
Performance & Financial Health Analysis: Praxis Precision Medicines Inc. vs Vaxcyte Inc.
| Metric | PRAX | PCVX |
|---|---|---|
| Market Information | ||
| Market Cap | $9.60B | $8.82B |
| Market Cap Category | Mid cap | Mid cap |
| 10 Day Avg. Volume | 391,453 | 1,010,564 |
| 90 Day Avg. Volume | 416,321 | 1,270,815 |
| Last Close | $264.54 | $49.56 |
| 52 Week Range | $37.19 - $366.52 | $29.08 - $65.00 |
| % from 52W High | -27.82% | -23.75% |
| All-Time High | $914.27 (Jan 04, 2021) | $121.06 (Sep 16, 2024) |
| % from All-Time High | -71.07% | -59.06% |
| Growth Metrics | ||
| Quarterly Revenue Growth | N/A | N/A |
| Quarterly Earnings Growth | -1.00% | N/A |
| Financial Health | ||
| Profit Margin (TTM) | 0.00% | 0.00% |
| Operating Margin (TTM) | 0.00% | 0.00% |
| Return on Equity (TTM) | -0.46% | -0.26% |
| Debt to Equity (MRQ) | 0.01 | 4.38 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $34.85 | $20.49 |
| Cash per Share (MRQ) | $21.52 | $10.85 |
| Operating Cash Flow (TTM) | $-249,068,000 | $-655,577,024 |
| Levered Free Cash Flow (TTM) | $-146,253,744 | $-430,852,864 |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | N/A | N/A |
Valuation & Enterprise Metrics Analysis: Praxis Precision Medicines Inc. vs Vaxcyte Inc.
| Metric | PRAX (Apr 26, 2026) | PCVX (Apr 24, 2026) |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | N/A | -10.79 |
| Forward P/E | -38.31 | -8.34 |
| PEG Ratio | -38.31 | -8.34 |
| Price to Sales (TTM) | N/A | N/A |
| Price to Book (MRQ) | 9.46 | 2.97 |
| Market Capitalization | ||
| Market Capitalization | $9.60B | $8.82B |
| Enterprise Value | $8.58B | $7.30B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | N/A | N/A |
| Enterprise to EBITDA | -26.32 | -8.05 |
| Risk & Other Metrics | ||
| Beta | 2.97 | 1.39 |
| Book Value per Share (MRQ) | $34.85 | $20.49 |
Financial Statements Comparison: Praxis Precision Medicines Inc. vs Vaxcyte Inc.
Financial Metrics
Loading Financial Charts...
Revenue
Operating Margin
Profit Margin
Long Term Debt
Income Flow Analysis
Financial Statements Comparison
Income Statement
| Metric | PRAX (2025) | PCVX (2025) |
|---|---|---|
| Revenue/Sales | 0 | 0 |
| Cost of Goods Sold | N/A | N/A |
| COGS % of Revenue | - | - |
| Gross Profit | N/A | N/A |
| Gross Margin | - | - |
| Research & Development | 267.12M | 794.31M |
| Operating Income (EBIT) | -326.20M | -923.68M |
| Operating Margin | - | - |
| EBITDA | -326.06M | -898.82M |
| EBITDA Margin | - | - |
| Pre-Tax Income | -303.27M | -766.63M |
| Pre-Tax Income % of Revenue | - | - |
| Income Tax | N/A | N/A |
| Income Tax % of Revenue | - | - |
| Net Income (Profit) | -303.27M | -766.63M |
| Profit Margin | - | - |
Balance Sheet & Liquidity Metrics
| Metric | PRAX (2025) | PCVX (2025) |
|---|---|---|
| Cash & Equivalents | 357.33M | 173.96M |
| Total Current Assets | 610.91M | 1.63B |
| Total Current Assets % of Revenue | - | - |
| Total Current Liabilities | 59.77M | 205.75M |
| Total Current Liabilities % of Revenue | - | - |
| Long-Term Debt | 0 | 111.36M |
| Long-Term Debt % of Revenue | - | - |
| Total Shareholders Equity | 878.14M | 2.69B |
| Retained Earnings | -1.14B | -2.15B |
| Retained Earnings % of Revenue | - | - |
| Property, Plant & Equipment | 415,000 | 178.56M |
Cash Flow Statement Comparison
| Metric | PRAX (2025) | PCVX (2025) |
|---|---|---|
| Operating Cash Flow | -257.32M | -641.04M |
| Operating Cash Flow % of Revenue | - | - |
| Capital Expenditures | -56,000 | -56.97M |
| Free Cash Flow | -249.12M | -712.55M |
| FCF Margin | - | - |
| Debt Repayment | N/A | N/A |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | PRAX | PCVX |
|---|---|---|
| Shares Short | 3.95M | 13.69M |
| Short Ratio | 9.07 | 10.38 |
| Short % of Float | 14.21% | 10.52% |
| Shares Outstanding | 25.20M | 131.06M |
| Float Shares | 25.78M | 132.23M |
| % Held by Insiders | 0.40% | 0.59% |
| % Held by Institutions | 106.12% | 104.46% |
| % Held by Public | -6.52% | -5.05% |
Dividend Analysis & Yield Comparison: Praxis Precision Medicines Inc. vs Vaxcyte Inc.
| Metric | PRAX | PCVX |
|---|---|---|
| Last 12-Month Dividend | N/A | N/A |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | N/A | N/A |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | N/A | N/A |
| Ex-Dividend Date | N/A | N/A |